Protein replacement startups are coming for food additives as Shiru launches from Y Combinator

Published August 16, 2019

Shiru, a new company that’s launching from the latest batch of Y Combinator-backed startups, is joining the ranks of the businesses angling for a spot at the vanguard of the new food technology revolution.

The company was founded by Jasmin Hume, the former director of food chemistry at Just (the company formerly known as Hampton Creek) and takes its name from a homophone of the Chinese shi rou (which Hume has roughly translated to an examination of meat). At Just, Hume was working with a team that was fractionating plants to look at their physical properties to identify what products could be made from the various proteins and chemicals researchers found in the plants.

Shiru, by contrast, is using computational biology to find the ideal proteins for specific applications in the food industry.

The company’s looking at what proteins are best for creating certain kinds of qualities that are used in food additives — things like viscosity building, solubility, foam stability, emulsification and binding, according to Hume.

In some ways, Hume’s approach looks similar to the early product roadmap for Geltor, a company backed by SOSV and IndieBio that was also looking to make functional proteins. The company, which has raised over $18 million to date, shifted its attention to proteins for the beauty industry and cosmetics instead of food — potentially leaving an opening for Shiru to exploit.

Still in its early days, Shiru doesn’t have a product nailed down yet, but the science the company is exploring is increasingly well understood, and Hume says it’s looking at several different genetically engineered feedstocks — from yeasts to undisclosed strains of bacteria and fungi to make its proteins.

“We use the power of molecular design and machine learning to identify protein structures that are more functional than existing alternatives,” says Hume. “The proteins that we are screening for are inspired by nature.”

Hume’s path to founding Shiru involves quite the pedigree. Before Just, she received her doctorate in materials chemistry from New York University, and she’d spent a stretch as a summer associate at the New York-based frontier technology-focused investment firm Lux Capital.

Hume expects to begin pilot production of initial proteins later this year and be producing small but repeatable quantities by the end of 2020.

The company hasn’t raised any outside capital before Y Combinator and is currently in the process of raising a round, Hume said.

Medivis has launched its augmented reality platform for surgical planning

Published February 13, 2019

After two years of development, Medivis, a New York-based company developing augmented reality data integration and visualization tools for surgeons, is bringing its first product to market.

The company was founded by Osamah Choudhry and Christopher Morley who met as senior residents at NYU Medical Center.

Initially a side-project, the two residents roped in some engineers to help develop their first prototypes and after a stint in NYU’s Summer Launchpad program the two decided to launch the company.

Now, with $2.3 million in financing led by Initialized Capital and partnerships with Dell and Microsoft to supply hardware, the company is launching its first product, called SurgicalAR.

In fact, it was the launch of the HoloLens that really gave Medivis its boost, according to Morley. That technology pointed a way toward what Morley said was one of the dreams for technology in the medical industry.

“The Holy Grail is to be able to holographically render a patient,” he said.

For now, Medivis is able to access patient data and represent it visually in a three-dimensional model for doctors to refer to as they plan surgeries. That model is mapped back to the patient to give surgeons a plan for how best to approach an operation.

“The interface between medical imaging and surgical utility from it is really where we see a lot of innovation being possible,” says Morley.

So far, Medivis has worked with the University of Pennsylvania and New York University to bring their prototypes into a surgical setting.

The company is integrating some machine learning capabilities to be able to identify the most relevant information from patients’ medical records and diagnostics as they begin to plan the surgical process.

“What we’ve been working on over this time is developing this really disruptive 3D pipeline,” says Morley. “What we have seen is that there is a distinct lack of 3D pipelines to allow people to directly interface… very quickly try to automate the entire rendering process.”

For now, Medivis is selling a touchscreen monitor, display and a headset. The device plugs into a hospital network and extracts medical imaging to display from their servers in about 30 seconds, according to Choudhry.

“That’s where we see this immediately being useful in that pre-surgical planning stage,” Choudhry says. “The use in surgical planning and being able to extend this through surgical navigation… Streamline the process that requires a large amount of pieces and components and setups so you only need an AR headset to localize pathology and make decisions off of that.”

Already the company has performed 15 surgeries in consultation with the company’s technology.

“When we first met Osamah and Chris, we immediately understood the magnitude of the problem they were out to solve. Medical imaging as it relates to surgical procedures has largely been neglected, leaving patients open to all sorts of complications and general safety issues,” said Eric Woersching, general partner, Initialized Capital, in a statement. “We took one look at the Medivis platform and knew they were poised to transform the operating room. Not only was their hands-free approach to visualization meeting a real need for greater surgical accuracy, but the team has the passion and expertise in the medical field to bring it all to fruition. We couldn’t be more thrilled to welcome Medivis to the Initialized family.”